The effect of traditional bone-tonic prescription on pain and bone density in patients with osteoporosis

Chinese Journal of Clinical Rehabilitation

Volumn 7, Issue 11, 2003, Pages 1666-1667

  Li, Qiaofeng ^a   Tan, Zhaohui ^a   Xie, Xiaoqing ^a   Chen, Ping ^a   Zhu, Pingxian ^a   Tang, Xiangyang ^a   Mao, Zhisen ^a  

^a Dept Bone Surgery People Hospital ^*  (China)

Author keywords

Bone density; Osteoporosis drug therapy; Pain

Indexed keywords

CALCITONIN; CALCIUM; CHINESE DRUG;

ANTINOCICEPTION; ARTICLE; BONE DENSITY; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTPATIENT; PAIN ASSESSMENT; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 2442556267     PISSN: 16715926     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Fang SM, Xue J, Qian ZX. Assessment of value of singh index in diagnosimg and teatimg osteoposis. Xiandai Kangfu(Mod Rehabil) 2001; 17(3); 191-3
2. Prince RL, Smith M, Dike ImM. Prevention of postemenopausal osteoprosis. A comparative study of exercise: Calcium supplementation and hormonereplacement therapy. N Engl J Med 1991; 325: 1189-95
3. Riggs BL, Khosla S, Meltion Lj. A unitary model for involuational osteoporsis: estrogen deficieny causes both type I and type IIosteoporosis in postmenopausal women and contributes to bone low in aging men. J Bone Miner Res 1998; 13: 763-73
4. Nordin BE, Need AG, Morris HA. Biochemical variables in pre-and postmenopausaj women: rexonxiling the calcium and estrogenhypotheses. Osteopors Int 1999; 9: 35-137
5. Arjmandi BH Salih MA, Herbert DC. Evience for estrogen receptor-linked calciu transport in the intestine. Bone Miner 1993; 21: 63-74
6. Eriksen EF, Lngdahl BL. The pathogenesis of osteorosis. Hormone Research 1997; 78-82
7. Boonen J, Awessens J, Dequeker J. Age-associated decline in human femoreal neck cortical and trabecuar content of insulin-like growt ctor-I: potential implications for age-related (type II) osteoporotic fracture occurrence. Calcified Tissue International 1997; 61: 173-8